These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 27161568

  • 1. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
    Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A.
    Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.
    BMC Cancer; 2015 Apr 08; 15():236. PubMed ID: 25885683
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM investigators.
    Lancet Oncol; 2015 Oct 08; 16(13):1344-54. PubMed ID: 26361969
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T.
    World J Gastroenterol; 2014 Sep 21; 20(35):12581-7. PubMed ID: 25253961
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T, Kurume Liver Cancer Study Group of Japan.
    Cancer Med; 2015 Dec 21; 4(12):1836-43. PubMed ID: 26471348
    [Abstract] [Full Text] [Related]

  • 12. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS.
    Oncotarget; 2017 Jul 18; 8(29):47555-47564. PubMed ID: 28548930
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
    Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660
    [Abstract] [Full Text] [Related]

  • 18. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT.
    JAMA; 2014 Jul 02; 312(1):57-67. PubMed ID: 25058218
    [Abstract] [Full Text] [Related]

  • 19. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 02; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 20. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M.
    Eur J Cancer; 2017 Nov 02; 86():106-114. PubMed ID: 28985579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.